Fosun Pharmaceutical announced that recently, its holding subsidiary Fosun Wanbang Pharmaceutical Group Co., Ltd., the drug registration application for engagliptin metformin extended-release tablets was approved by the State Drug Administration. The approved indication is to improve blood sugar control in adult patients with type 2 diabetes who are being treated with engagliptin and metformin hydrochloride. As of June 2026, the group has invested a total of about 17.92 million yuan in research and development of this drug. In 2025, the sales volume of metformin englicin tablets in China was approximately 674 million yuan. The approval of the drug will enrich the Group's product line, but the sales situation is uncertain.

Fosun Pharmaceutical announced that recently, its holding subsidiary Fosun Wanbang Pharmaceutical Group Co., Ltd., the drug registration application for engagliptin metformin extended-release tablets was approved by the State Drug Administration. The approved indication is to improve blood sugar control in adult patients with type 2 diabetes who are being treated with engagliptin and metformin hydrochloride. As of June 2026, the group has invested a total of about 17.92 million yuan in research and development of this drug. In 2025, the sales volume of metformin englicin tablets in China was approximately 674 million yuan. The approval of the drug will enrich the Group's product line, but the sales situation is uncertain.